- Home
- / Elicera Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Elicera Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
KR2
2024-10-29
Market Capitalization
KR71.9 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 10, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| SEK | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross profit | 1.0K | 1.3M | 11.2M | 7.1M | 10.9M | |||
| Operating expense total | 4.0K | 194.0K | 2.8M | 13.1M | 20.6M | 28.3M | 24.0M | 28.8M |
| Depreciation and amortization | 12.0K | 12.0K | 12.0K | 12.0K | 12.0K | |||
| EBITDA | (4.0K) | (194.0K) | (2.8M) | (13.1M) | (19.4M) | (17.1M) | (16.9M) | (17.9M) |
| EBIT | (4.0K) | (194.0K) | (2.8M) | (13.1M) | (19.4M) | (17.1M) | (16.9M) | (17.9M) |
| Interest income | 53.0K | 774.0K | 827.0K | 546.0K | ||||
| Interest expense | 1.0K | 129.0K | 76.0K | 53.0K | 8.0K | |||
| Pre tax profit | (4.0K) | (191.0K) | (2.8M) | (13.1M) | (19.4M) | (16.4M) | (16.1M) | (17.4M) |
| Net Income | (4.0K) | (191.0K) | (2.8M) | (13.1M) | (19.4M) | (16.4M) | (16.1M) | (17.4M) |